2021 PTAB Year in Review: Analysis & Trends: Biologics at the PTAB: Statistics and Insights into Notable Biologics Decisions | Sterne, Kessler, Goldstein & Fox P.L.L.C.

In June 2021, the US Patent and Trademark Office (USPTO) published an update to its study of America Invents Act (AIA) trials involving challenges to Orange Book-listed and biologic...

Related Keywords

Delaware ,United States ,America ,Adello Biologics ,Sanofi Aventis Deutschland Gmb ,Goldstein Fox ,Coherus Biosciences ,Fresenius Kabi ,Genentech Avastin ,Amgen ,Genentech ,Coherus Biosciences Inc ,Institution Decision ,Biogen Inc ,Celltrion Inc ,Pfizer ,Trademark Office ,Pfizer Inc ,See Adello Biologics ,Pilot Program ,Tanvex Biopharma United States Inc ,Mylan Inc ,Fresenius Kabi United States ,Genentech Inc ,Tox Inc ,Inst Inc ,Fresenius ,Pilot Program Concerning Motion To Amend Practice ,Hospira Inc ,Amgen Inc ,Mylan Pharmaceuticals Inc ,America Invents Act ,Orange Book Listed ,Orange Book ,Appeal Board ,Patent Owners ,Rituxan Label ,Office Manager ,Internet Archives ,Patent Owner ,Federal Circuit ,Botulinum Toxin Galderma ,Program Concerning Motion ,Amend Practice ,Preliminary Guidance ,Lupin Limited ,Tanvex Biopharma United States ,Accord Biopharma ,Insulin Glargine ,Mylan Pharmaceuticals ,Aventis Deutschland Gmbh ,Kabi United States ,Biopharma United States ,Sanofi Aventis Deutschland Gmbh ,